Hedyeh Ebrahimi (@ebrahimihedyeh) 's Twitter Profile
Hedyeh Ebrahimi

@ebrahimihedyeh

MD, MPH - Postdoctoral fellow at @CityofHope_GU

ID: 1130162273803280384

calendar_today19-05-2019 17:24:18

692 Tweet

878 Followers

1,1K Following

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

This is such an elegant paper about renal cell cancer tumor metabolism in nature : TCA cycle is suppressed in primary ccRCC but ENHANCED in metastatic ccRCC: work in humans and mice! Much respect DeBerardinis Lab and Team UT Southwestern Medical Center

Tanya Dorff (@tdorffonc) 's Twitter Profile Photo

Our 1st ⁦City of Hope⁩ GU program retreat was an unforgettable day of science and camaraderie. From immunotherapy to theranostics, microbiome to transcriptomics, we are ready to bring hope to all those with GU cancer as our program expands in CA, AZ, Chicago and Atlanta!

Our 1st ⁦<a href="/cityofhope/">City of Hope</a>⁩ GU program retreat was an unforgettable day of science and camaraderie. From immunotherapy to theranostics, microbiome to transcriptomics, we are ready to bring hope to all those with GU cancer as our program expands in CA, AZ, Chicago and Atlanta!
Sarah P. Psutka MD MS (@spsutkamd) 's Twitter Profile Photo

It truly takes a village - one that spanned the GLOBE 🌎! Thank you and congratulations to all of our co-authors for their and to the amazing #SophiaChahine, UW Medicine medical student, who led this work describing a rare and extremely challenging disease state in #TestisCancer

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

1/ Results from #LITESPARK-005 are out <a href="/NEJM/">NEJM</a>! 
The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) <a href="/US_FDA/">U.S. FDA</a> approval Dec 2023 in pretreated pts w/ #ccRCC. 
Presentation #ESMO24 @myEsmo

Check it out: nejm.org/doi/full/10.10…
Shuchi Gulati MD (@shuchigulati) 's Twitter Profile Photo

Phenomenal talk from the master himself Sumanta K. Pal, MD, FASCO on the role of gut microbiome to optimize immunotherapy in cancer. Showcasing the work his group has done with Nazli Dizman Hedyeh Ebrahimi with back to back nature papers Promising avenue that will lay the foundation for a SWOG Cancer Research Network

Phenomenal talk from the master himself <a href="/montypal/">Sumanta K. Pal, MD, FASCO</a> on the role of gut microbiome to optimize immunotherapy in cancer. Showcasing the work his group has done with <a href="/NazliDizman/">Nazli Dizman</a> <a href="/EbrahimiHedyeh/">Hedyeh Ebrahimi</a> with back to back <a href="/Nature/">nature</a> papers
Promising avenue that will lay the foundation for a <a href="/SWOG/">SWOG Cancer Research Network</a>
Ziad Bakouny, MD, MSc (@ziadbakouny) 's Twitter Profile Photo

Thank you chadi nabhan MD, MBA, FACP for hosting us (IMG Oncologists) again on #HealthcareUnfiltered to discuss our efforts as part of the ASCO IMG Community of Practice to support IMGs in oncology. Check out the podcast when it comes out tmrw! Nazli Dizman Toni Choueiri, MD MSK Department of Medicine

Cristiane D Bergerot (@crisbergerot) 's Twitter Profile Photo

Combining telehealth & ePROs is transforming oncology with enhanced accessibility, quality, and patient satisfaction Read more about these innovations in our latest post at ASCO Post, co-written w Mazie Tsang, MD, MAS, MS Ramy Sedhom, MD #ASCODailyNews #ASCOQLTY24 dailynews.ascopubs.org/do/advancing-e…

Combining telehealth &amp; ePROs is transforming oncology with enhanced accessibility, quality, and patient satisfaction

Read more about these innovations in our latest post at <a href="/ASCO/">ASCO</a> Post, co-written w <a href="/MazieTsangMD/">Mazie Tsang, MD, MAS, MS</a> <a href="/ramsedhom/">Ramy Sedhom, MD</a> #ASCODailyNews #ASCOQLTY24

dailynews.ascopubs.org/do/advancing-e…
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Just in <a href="/Annals_Oncology/">Annals of Oncology</a> 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 <a href="/urotoday/">UroToday.com</a> <a href="/OncoAlert/">OncoAlert</a>  <a href="/kidneycan/">KidneyCAN</a> <a href="/huntsmancancer/">Huntsman Cancer Institute</a>